James Brumley

James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

SHLD Stock: Sears CEO Eddie Lampert Is a Cheerleader, Not a Coach

By James Brumley, InvestorPlace Feature Writer

The latest letter from Eddie Lampert about the future of Sears might excite some SHLD stock holders, but the message is starting to ring hollow.

Don’t Count on OTC Lipitor as an Rx for Higher PFE Stock

By James Brumley, InvestorPlace Feature Writer

PFE stock holders are looking forward to cholesterol reducer Lipitor becoming an OTC drug, but Pfizer shareholders may have a long and disappointing wait.

New FDA Label Rules: Fear Not, Junk-Food Makers!

By James Brumley, InvestorPlace Feature Writer

The recently proposed changes to FDA label rules for food and drink producers seems troubling for these food stocks, but...

Hate the Brand, Love the Stock

By James Brumley, InvestorPlace Feature Writer

Contrary to popular belief, investing in a stock isn't a matter of morality or respect for fellow humans. It's all about the Benjamins, and these hated companies dole 'em out.

SHLD Stock: Don’t Focus on Earnings When Sears Reports Earnings

By James Brumley, InvestorPlace Feature Writer

Here's what current and potential SHLD stock holders need to know about Thursday's Sears earnings report and conference call.

5 Biotech Stocks That Are Buyout Candidates

By James Brumley, InvestorPlace Feature Writer

These biotech stocks are this year's top M&A candidates. But even if they're not acquired, they're solid biopharma investments.

For-Profit Schools Can’t Dodge This Bullet Any Longer

By James Brumley, InvestorPlace Feature Writer

For-profit schools like Corinthian College, Apollo Education and Strayer are forced to defend themselves, and as it turns out, they’re not well-armed.

This Biotech Bubble Is Bound to Burst

By James Brumley, InvestorPlace Feature Writer

Biotech stocks have been hot thanks to a wave of M&A speculation. That wave, however, has run its course, putting these stocks and biotech ETFs at risk.

YNDX, BIDU or GOOG: Which Is the Best Search Stock?

By James Brumley, InvestorPlace Feature Writer

GOOG may have set the bar, but YNDX stock and BIDU stock have managed to replicate the search giant's success in their respective markets. Which is best?

SCTY Stock Continues Crushing Other Solar Stocks

By James Brumley, InvestorPlace Feature Writer

SCTY stock is blowing other solar stocks out of the water. Here's why First Solar and others can't keep up with SolarCity.

Load More